OSCR · NYSE · Medical - Healthcare Plans

Oscar Health (OSCR)

Offers ACA individual-market health plans, ICHRA coverage, and enrollment technology.

$30.34
vs last close−0.95 (−3.04%)
Loading prices…

Oscar Health, Inc.OSCR
Health Care

Sells ACA individual-market health plans, including employer-funded ICHRA coverage, and earns most revenue from premiums. An internally built insurance platform supports member navigation and plan operations, while +Oscar, Lucie Health Marketplace, Trove Group, and HealthInsurance.org extend its technology, enrollment, brokerage, and lead-generation capabilities.

Offers Affordable Care Act health plans to individuals, families, and employees using employer-funded ICHRAs across multiple U.S. states, with enrollment concentrated in Florida and Texas. Most revenue comes from insurance premiums; +Oscar sells Campaign Builder engagement technology to providers and payors.

Runs member navigation, utilization management, claims, billing, and benefits on an internally built cloud platform. Lucie Health Marketplace handles plan shopping and enrollment; Trove Group sells individual medical and supplemental coverage; HealthInsurance.org provides education and leads.

Results depend on pricing medical risk, managing claims and risk adjustment, maintaining provider networks, and meeting federal and state rate, capital, and medical-loss-ratio rules. Market participation is renewed annually, and federal advance tax credits fund most premium receipts.

Company facts

CEOMark Thomas Bertolini
ListedMar 3, 2021
ExchangeNYSE
HeadquartersNew York City, NY
CountryUnited States
Employees2,305
CIK0001568651
ISINUS6877931096

Market cap$8.11B
EPS (ttm)$1.40
P/E (ttm)22.35
ROE38.5%
P/B3.95
P/S0.5296
Dividend yieldDiv yield
Beta1.47vs XLV 0.62

Price target$33.50+7.1%Average of 13 analysts
ConsensusHold8 of 13 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 18, 2026Raymond JamesReiterate
Rating: Target: $30
Rating: OutperformTarget: $42
Sep 17, 2026Piper SandlerReiterate
Rating: Target: $36
Rating: OverweightTarget: $48
Sep 17, 2026Robert W. BairdTarget
Target: $27
Target: $33
Sep 17, 2026Goldman SachsReiterate
Rating: Target: $30
Rating: NeutralTarget: $34
Sep 17, 2026BarclaysReiterate
Rating: Target: $39
Rating: OverweightTarget: $49

Next report
Nov 9, 26
estimated · in 48 days
EPS estimate
−$0.14
Revenue estimate
$4.69B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.62$0.92−$0.89−$0.53−$1.24$2.07$1.10Pending
Estimate−$0.55$0.83−$0.90−$0.55−$0.92$1.21$0.40−$0.14
Surprise−12.7%+10.8%+1.1%+3.6%−34.6%+71.1%+173.0%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$2.39B$3.05B$2.86B$2.99B$2.75B$4.58B$4.79BPending
Estimate$2.83B$2.78B$3.07B$3.05B$3.12B$4.89B$4.73B$4.69B
Surprise−15.3%+9.6%−6.8%−2.2%−12.1%−6.4%+1.3%
Estimate−$0.14
ReportedDue Nov 9, 2026
Estimate$4.69B
ReportedDue Nov 9, 2026
View details

Debt to equity21.00%
Current ratio107.90%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$2.42B$2.39B$3.05B$2.86B$2.99B$2.81B$4.65B$4.88B
Net income−$54.6M−$153.5M$275.3M−$228.4M−$137.5M−$352.6M$679.0M$361.8M
Net margin0.0%0.0%9.0%0.0%0.0%0.0%14.6%7.4%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income−$52.3M−$147.7M$297.1M−$230.5M−$129.3M−$333.7M$704.1M$383.0M
YoY growthLoss narrowedLoss narrowed+66.5%Turned lossLoss widenedLoss widened+137.0%Turned profit

Balance sheet, Jun 30, 2026Cash & short-term investments $8.56B · Total debt $431.6M · Total assets $11.23B · Shareholders' equity $2.05B

Revenue
$4.88B
Operating income
$383.0M
Net income
$361.8M
View details

No dividends on record.

Institutions66.44%200.30M shares
443 holders · as of Jun 30, 2026
Insiders27.02%81.46M shares
18 holders · as of Sep 18, 2026
Strategic holders2.05%6.18M shares
1 holder · as of Sep 18, 2026
Other4.49%13.55M shares
remainder

301.49M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Two share counts disagree (301.49M in the company's Sep 22, 2026 report, 259.27M elsewhere); stakes use the report.

This company has 2 share classes; every stake here is a share of the whole company.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
Joshua KushnerInsider
12.45%37.53Mfiled Sep 18, 2026
Joshua Kushner1Insiderdirector, 10 percent owner, officer: Co-Founder and Vice Chairman
9.70%29.25M Bfiled Sep 18, 2026
BlackRock, Inc.Institution
6.83%20.59M Aas of Jun 30, 2026
T. Rowe Price Investment Management, Inc.Institution
4.32%13.04M Aas of Jun 30, 2026
D. E. Shaw & Co., Inc.Institution
4.19%12.64M Aas of Jun 30, 2026
  1. Joshua Kushner reports a block also reported by another filer; it is counted once, under that filer.

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Sep 3, 2026Janet Liangofficer: President, Oscar Insurance−10,360$31.45
Sep 3, 2026Mario Schlosserdirector−31,422$31.45
Sep 3, 2026Adam McAnaneyofficer: Chief Legal Officer−9,092$31.45
Sep 3, 2026Richard Scott Blackleyofficer: Chief Financial Officer−28,869$31.45
Sep 3, 2026Victoria Baltrusofficer: Chief Accounting Officer−958$31.45
View details

  • Centene

    Ambetter is the largest ACA marketplace rival

  • Elevance Health

    Anthem and Wellpoint overlap in ACA public exchanges

  • UnitedHealth Group

    UnitedHealthcare pressures exchange pricing and networks

  • Molina Healthcare

    Medicaid-style cost control overlaps in marketplace plans

  • Cigna

    Cigna is a smaller but current ACA exchange peer

Compare

CompanyPriceChange
Oscar Health$30.34−3.04%$8.11B22.414.30.5+67.2%
Centene$63.73−1.94%$32.10B14.10.2+9.9%
Elevance Health$402.70−1.61%$88.77B18.214.80.4+0.8%
UnitedHealth Group$373.99−0.95%$342.88B24.317.50.8+0.4%
Molina Healthcare$191.79−3.04%$10.33B1,041.127.20.2−4.8%
Cigna$274.76+0.11%$72.53B11.48.70.3+6.6%
Median21.214.80.3+0.8%